Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis
The risk of cancer developing in people with psoriasis has raised some concern, with little clarity regarding differentiation in risk according to psoriasis severity. To conduct a systematic review and meta-analysis of observational studies on the risk of cancer incidence and mortality in people wit...
Uloženo v:
| Vydáno v: | JAMA dermatology (Chicago, Ill.) Ročník 155; číslo 12; s. 1390 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.12.2019
|
| Témata: | |
| ISSN: | 2168-6084, 2168-6084 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The risk of cancer developing in people with psoriasis has raised some concern, with little clarity regarding differentiation in risk according to psoriasis severity.
To conduct a systematic review and meta-analysis of observational studies on the risk of cancer incidence and mortality in people with psoriasis.
Six electronic databases (MEDLINE, Embase, MEDLINE in Process, Cochrane Central Register, Web of Science, and LILACS [Literatura Latino-Americana e do Caribe em Ciências da Saúde]) were searched from inception to November 15, 2017, for eligible studies.
Cohort and case-control studies that provided estimates of the risk of cancer incidence or cancer mortality associated with psoriasis were included.
Data were extracted relating to study design, study population, and risk estimates. Study-specific estimates of the relative risk (RR) were combined using a random-effects model. Heterogeneity was quantified using the I2 statistic. Data were analyzed from April 9, 2018, through February 22, 2019.
Pooled RR estimates for cancer incidence and cancer mortality for psoriasis cohorts compared with people without psoriasis.
A total of 58 unique studies were included, with quality varying for the incidence and the mortality studies. Severe psoriasis (RR, 1.22; 95% CI, 1.08-1.39 [9 studies]) and all severities of psoriasis (RR, 1.18; 95% CI, 1.06-1.31 [7 studies]) were associated with an increased risk of cancer (overall), and associations were found for a range of site-specific cancers, including colon (RR, 1.18 [95% CI, 1.03-1.35]), colorectal (RR, 1.34 [95% CI, 1.06-1.70]), kidney (RR, 1.58 [95% CI, 1.11-2.24]), laryngeal (RR, 1.79 [95% CI, 1.06-3.01]), liver (RR, 1.83 [95% CI, 1.28-2.61]), lymphoma (RR, 1.40 [95% CI, 1.24-1.57]), non-Hodgkin lymphoma (RR, 1.28 [95% CI, 1.15-1.43]), keratinocyte cancers (RR, 1.71 [95% CI, 1.08-2.71]), esophageal (RR, 2.05 [95% CI, 1.04-4.07]), oral cavity (RR, 2.80 [95% CI, 1.99-3.93]), and pancreatic (RR, 1.41 [95% CI, 1.16-1.73]). Overall cancer mortality risk was higher in patients with severe psoriasis (RR, 1.22; 95% CI, 1.08-1.38 [4 studies]). Specifically, liver (RR, 1.43 [95% CI, 1.09-1.88]), esophageal (RR, 2.53 [95% CI, 1.87-3.41]), and pancreatic (RR, 1.31 [95% CI, 1.02-1.69]) cancer mortality were found to be elevated in those with severe psoriasis. The heterogeneity of estimates was often very high despite stratification. Marked attenuation of risk was found in those studies that adjusted estimates for smoking, alcohol consumption, and obesity.
In this study, people with psoriasis appeared to have an increased risk of cancer incidence and cancer-related mortality involving a range of site-specific cancers. Future research examining specific lifestyle factors, treatments, and the inflammatory processes that contribute to psoriasis may help provide additional information on the underlying mechanisms for the apparent increased cancer risk. |
|---|---|
| AbstractList | The risk of cancer developing in people with psoriasis has raised some concern, with little clarity regarding differentiation in risk according to psoriasis severity.ImportanceThe risk of cancer developing in people with psoriasis has raised some concern, with little clarity regarding differentiation in risk according to psoriasis severity.To conduct a systematic review and meta-analysis of observational studies on the risk of cancer incidence and mortality in people with psoriasis.ObjectiveTo conduct a systematic review and meta-analysis of observational studies on the risk of cancer incidence and mortality in people with psoriasis.Six electronic databases (MEDLINE, Embase, MEDLINE in Process, Cochrane Central Register, Web of Science, and LILACS [Literatura Latino-Americana e do Caribe em Ciências da Saúde]) were searched from inception to November 15, 2017, for eligible studies.Data SourcesSix electronic databases (MEDLINE, Embase, MEDLINE in Process, Cochrane Central Register, Web of Science, and LILACS [Literatura Latino-Americana e do Caribe em Ciências da Saúde]) were searched from inception to November 15, 2017, for eligible studies.Cohort and case-control studies that provided estimates of the risk of cancer incidence or cancer mortality associated with psoriasis were included.Study SelectionCohort and case-control studies that provided estimates of the risk of cancer incidence or cancer mortality associated with psoriasis were included.Data were extracted relating to study design, study population, and risk estimates. Study-specific estimates of the relative risk (RR) were combined using a random-effects model. Heterogeneity was quantified using the I2 statistic. Data were analyzed from April 9, 2018, through February 22, 2019.Data Extraction and SynthesisData were extracted relating to study design, study population, and risk estimates. Study-specific estimates of the relative risk (RR) were combined using a random-effects model. Heterogeneity was quantified using the I2 statistic. Data were analyzed from April 9, 2018, through February 22, 2019.Pooled RR estimates for cancer incidence and cancer mortality for psoriasis cohorts compared with people without psoriasis.Main Outcomes and MeasuresPooled RR estimates for cancer incidence and cancer mortality for psoriasis cohorts compared with people without psoriasis.A total of 58 unique studies were included, with quality varying for the incidence and the mortality studies. Severe psoriasis (RR, 1.22; 95% CI, 1.08-1.39 [9 studies]) and all severities of psoriasis (RR, 1.18; 95% CI, 1.06-1.31 [7 studies]) were associated with an increased risk of cancer (overall), and associations were found for a range of site-specific cancers, including colon (RR, 1.18 [95% CI, 1.03-1.35]), colorectal (RR, 1.34 [95% CI, 1.06-1.70]), kidney (RR, 1.58 [95% CI, 1.11-2.24]), laryngeal (RR, 1.79 [95% CI, 1.06-3.01]), liver (RR, 1.83 [95% CI, 1.28-2.61]), lymphoma (RR, 1.40 [95% CI, 1.24-1.57]), non-Hodgkin lymphoma (RR, 1.28 [95% CI, 1.15-1.43]), keratinocyte cancers (RR, 1.71 [95% CI, 1.08-2.71]), esophageal (RR, 2.05 [95% CI, 1.04-4.07]), oral cavity (RR, 2.80 [95% CI, 1.99-3.93]), and pancreatic (RR, 1.41 [95% CI, 1.16-1.73]). Overall cancer mortality risk was higher in patients with severe psoriasis (RR, 1.22; 95% CI, 1.08-1.38 [4 studies]). Specifically, liver (RR, 1.43 [95% CI, 1.09-1.88]), esophageal (RR, 2.53 [95% CI, 1.87-3.41]), and pancreatic (RR, 1.31 [95% CI, 1.02-1.69]) cancer mortality were found to be elevated in those with severe psoriasis. The heterogeneity of estimates was often very high despite stratification. Marked attenuation of risk was found in those studies that adjusted estimates for smoking, alcohol consumption, and obesity.ResultsA total of 58 unique studies were included, with quality varying for the incidence and the mortality studies. Severe psoriasis (RR, 1.22; 95% CI, 1.08-1.39 [9 studies]) and all severities of psoriasis (RR, 1.18; 95% CI, 1.06-1.31 [7 studies]) were associated with an increased risk of cancer (overall), and associations were found for a range of site-specific cancers, including colon (RR, 1.18 [95% CI, 1.03-1.35]), colorectal (RR, 1.34 [95% CI, 1.06-1.70]), kidney (RR, 1.58 [95% CI, 1.11-2.24]), laryngeal (RR, 1.79 [95% CI, 1.06-3.01]), liver (RR, 1.83 [95% CI, 1.28-2.61]), lymphoma (RR, 1.40 [95% CI, 1.24-1.57]), non-Hodgkin lymphoma (RR, 1.28 [95% CI, 1.15-1.43]), keratinocyte cancers (RR, 1.71 [95% CI, 1.08-2.71]), esophageal (RR, 2.05 [95% CI, 1.04-4.07]), oral cavity (RR, 2.80 [95% CI, 1.99-3.93]), and pancreatic (RR, 1.41 [95% CI, 1.16-1.73]). Overall cancer mortality risk was higher in patients with severe psoriasis (RR, 1.22; 95% CI, 1.08-1.38 [4 studies]). Specifically, liver (RR, 1.43 [95% CI, 1.09-1.88]), esophageal (RR, 2.53 [95% CI, 1.87-3.41]), and pancreatic (RR, 1.31 [95% CI, 1.02-1.69]) cancer mortality were found to be elevated in those with severe psoriasis. The heterogeneity of estimates was often very high despite stratification. Marked attenuation of risk was found in those studies that adjusted estimates for smoking, alcohol consumption, and obesity.In this study, people with psoriasis appeared to have an increased risk of cancer incidence and cancer-related mortality involving a range of site-specific cancers. Future research examining specific lifestyle factors, treatments, and the inflammatory processes that contribute to psoriasis may help provide additional information on the underlying mechanisms for the apparent increased cancer risk.Conclusions and RelevanceIn this study, people with psoriasis appeared to have an increased risk of cancer incidence and cancer-related mortality involving a range of site-specific cancers. Future research examining specific lifestyle factors, treatments, and the inflammatory processes that contribute to psoriasis may help provide additional information on the underlying mechanisms for the apparent increased cancer risk. The risk of cancer developing in people with psoriasis has raised some concern, with little clarity regarding differentiation in risk according to psoriasis severity. To conduct a systematic review and meta-analysis of observational studies on the risk of cancer incidence and mortality in people with psoriasis. Six electronic databases (MEDLINE, Embase, MEDLINE in Process, Cochrane Central Register, Web of Science, and LILACS [Literatura Latino-Americana e do Caribe em Ciências da Saúde]) were searched from inception to November 15, 2017, for eligible studies. Cohort and case-control studies that provided estimates of the risk of cancer incidence or cancer mortality associated with psoriasis were included. Data were extracted relating to study design, study population, and risk estimates. Study-specific estimates of the relative risk (RR) were combined using a random-effects model. Heterogeneity was quantified using the I2 statistic. Data were analyzed from April 9, 2018, through February 22, 2019. Pooled RR estimates for cancer incidence and cancer mortality for psoriasis cohorts compared with people without psoriasis. A total of 58 unique studies were included, with quality varying for the incidence and the mortality studies. Severe psoriasis (RR, 1.22; 95% CI, 1.08-1.39 [9 studies]) and all severities of psoriasis (RR, 1.18; 95% CI, 1.06-1.31 [7 studies]) were associated with an increased risk of cancer (overall), and associations were found for a range of site-specific cancers, including colon (RR, 1.18 [95% CI, 1.03-1.35]), colorectal (RR, 1.34 [95% CI, 1.06-1.70]), kidney (RR, 1.58 [95% CI, 1.11-2.24]), laryngeal (RR, 1.79 [95% CI, 1.06-3.01]), liver (RR, 1.83 [95% CI, 1.28-2.61]), lymphoma (RR, 1.40 [95% CI, 1.24-1.57]), non-Hodgkin lymphoma (RR, 1.28 [95% CI, 1.15-1.43]), keratinocyte cancers (RR, 1.71 [95% CI, 1.08-2.71]), esophageal (RR, 2.05 [95% CI, 1.04-4.07]), oral cavity (RR, 2.80 [95% CI, 1.99-3.93]), and pancreatic (RR, 1.41 [95% CI, 1.16-1.73]). Overall cancer mortality risk was higher in patients with severe psoriasis (RR, 1.22; 95% CI, 1.08-1.38 [4 studies]). Specifically, liver (RR, 1.43 [95% CI, 1.09-1.88]), esophageal (RR, 2.53 [95% CI, 1.87-3.41]), and pancreatic (RR, 1.31 [95% CI, 1.02-1.69]) cancer mortality were found to be elevated in those with severe psoriasis. The heterogeneity of estimates was often very high despite stratification. Marked attenuation of risk was found in those studies that adjusted estimates for smoking, alcohol consumption, and obesity. In this study, people with psoriasis appeared to have an increased risk of cancer incidence and cancer-related mortality involving a range of site-specific cancers. Future research examining specific lifestyle factors, treatments, and the inflammatory processes that contribute to psoriasis may help provide additional information on the underlying mechanisms for the apparent increased cancer risk. |
| Author | Parisi, Rosa Kontopantelis, Evangelos Trafford, Alex M Ashcroft, Darren M Griffiths, Christopher E M |
| Author_xml | – sequence: 1 givenname: Alex M surname: Trafford fullname: Trafford, Alex M organization: Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom – sequence: 2 givenname: Rosa surname: Parisi fullname: Parisi, Rosa organization: Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom – sequence: 3 givenname: Evangelos surname: Kontopantelis fullname: Kontopantelis, Evangelos organization: School of Health Sciences, National Institute for Health Research (NIHR) School of Primary Care Research, Division of Population Health, Faculty of Biology, Medicine, and Health, Health Services Research and Primary Care, University of Manchester, Manchester, United Kingdom – sequence: 4 givenname: Christopher E M surname: Griffiths fullname: Griffiths, Christopher E M organization: Dermatology Centre, NIHR Manchester Biomedical Research Centre, Faculty of Biology, Medicine, and Health, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom – sequence: 5 givenname: Darren M surname: Ashcroft fullname: Ashcroft, Darren M organization: Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31617868$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUEtPwzAYi9AQG2N_YcqRS8eX9JGU27TxkoZAA8SxStNvLKNNRtMN9d9TYEj4Yku2LMunpGedRULGDCYMgF1sVKUKrCvVuHLCgaWTEOLkiAw4S2SQgIx6_3SfjLzfQAcJEIXshPRDljAhEzkgduq900Y1xlnqVvTRu9oobzx9Nc2aNmukS-Pfv6057rF0W2PfqKvpvP0RKzpTVmN9Saf0qfUNdqOMpkvcG_ykyhb0HhsVKKvKtms9I8crVXocHXhIXq6vnme3weLh5m42XQQqYmETFDoVWKQQJoJBHkeaac7DFEScC6GEglzmIBJeRCByLbUo4lRLDOOYQ4Ra8iE5_-3d1u5jh77JKuM1lqWy6HY-4yEk3UGcxV10fIju8gqLbFubStVt9vcR_wK3eG3i |
| CitedBy_id | crossref_primary_10_1111_jdv_18663 crossref_primary_10_3390_cancers17132116 crossref_primary_10_1016_j_jaad_2020_10_045 crossref_primary_10_1016_j_jaad_2021_01_084 crossref_primary_10_3390_biomedicines10081976 crossref_primary_10_1017_S0954422423000185 crossref_primary_10_3390_cancers13225619 crossref_primary_10_1186_s12885_025_13920_8 crossref_primary_10_1016_j_jaut_2024_103187 crossref_primary_10_1093_rheumatology_keae294 crossref_primary_10_1111_phpp_12956 crossref_primary_10_1155_2022_7053613 crossref_primary_10_1007_s40744_024_00734_6 crossref_primary_10_1016_j_radonc_2020_08_016 crossref_primary_10_1002_aisy_202400558 crossref_primary_10_1016_j_autrev_2023_103444 crossref_primary_10_1111_dth_14433 crossref_primary_10_1016_j_clnu_2025_05_014 crossref_primary_10_3389_fmed_2022_998815 crossref_primary_10_1080_14712598_2025_2471093 crossref_primary_10_1007_s12672_025_02679_w crossref_primary_10_1080_1744666X_2020_1754194 crossref_primary_10_1371_journal_pone_0254661 crossref_primary_10_1002_mus_28196 crossref_primary_10_1055_a_2338_3716 crossref_primary_10_1080_14740338_2020_1746267 crossref_primary_10_1016_j_jaad_2023_03_035 crossref_primary_10_1038_s41556_023_01120_0 crossref_primary_10_1186_s12885_025_14243_4 crossref_primary_10_3390_cancers15092451 crossref_primary_10_3389_fimmu_2025_1651517 crossref_primary_10_1111_bjd_20624 crossref_primary_10_1155_2022_3261300 crossref_primary_10_2147_DMSO_S273147 crossref_primary_10_3389_fonc_2024_1366958 crossref_primary_10_1111_jop_13218 crossref_primary_10_1001_jamadermatol_2025_2056 crossref_primary_10_1016_j_jdcr_2020_08_032 crossref_primary_10_3390_cancers16244224 crossref_primary_10_1016_j_aohep_2023_101105 crossref_primary_10_1136_rmdopen_2022_002874 crossref_primary_10_12688_wellcomeopenres_17505_2 crossref_primary_10_2147_PTT_S328572 crossref_primary_10_12688_wellcomeopenres_17505_1 crossref_primary_10_1080_14740338_2020_1709440 crossref_primary_10_12688_wellcomeopenres_17505_3 crossref_primary_10_1111_srt_13782 crossref_primary_10_1016_j_ad_2024_02_013 crossref_primary_10_3390_diagnostics11101903 crossref_primary_10_4103_ijd_ijd_1095_23 crossref_primary_10_1155_2022_9188553 crossref_primary_10_1111_jdv_16683 crossref_primary_10_1016_j_ad_2024_05_011 crossref_primary_10_23736_S2784_8671_25_08192_7 crossref_primary_10_1016_j_phymed_2024_155612 crossref_primary_10_1093_ced_llae503 crossref_primary_10_1007_s40744_021_00397_7 crossref_primary_10_1055_a_2338_3533 crossref_primary_10_1002_jso_27017 crossref_primary_10_3390_ijms21197041 crossref_primary_10_1002_jvc2_285 crossref_primary_10_1007_s15006_019_1073_8 crossref_primary_10_3389_fimmu_2022_880201 crossref_primary_10_3389_fimmu_2023_1201167 crossref_primary_10_1155_2024_5058607 crossref_primary_10_1111_1346_8138_17950 crossref_primary_10_3390_life13010181 crossref_primary_10_1111_1346_8138_17695 crossref_primary_10_1016_j_rdc_2020_04_001 crossref_primary_10_3390_ph15111365 crossref_primary_10_1007_s13555_023_00905_3 crossref_primary_10_1038_s41598_022_23518_w crossref_primary_10_1016_j_jaad_2023_11_039 crossref_primary_10_3892_ijmm_2020_4612 crossref_primary_10_1093_ced_llaf172 crossref_primary_10_3390_ijms232012291 crossref_primary_10_1002_ijc_34180 crossref_primary_10_2340_actadv_v104_18487 crossref_primary_10_1080_10428194_2023_2232488 crossref_primary_10_1016_j_surge_2023_03_003 crossref_primary_10_1007_s00403_020_02101_1 crossref_primary_10_1007_s12672_025_03305_5 crossref_primary_10_7759_cureus_19490 crossref_primary_10_1093_bjd_ljad479 crossref_primary_10_23203_JKSP_2024_21_2_65 crossref_primary_10_1038_s41467_024_51824_6 crossref_primary_10_1093_ced_llaf184 crossref_primary_10_3390_app11188366 crossref_primary_10_1007_s00432_023_05387_6 crossref_primary_10_1038_s41416_023_02172_7 crossref_primary_10_1016_j_intimp_2024_113508 crossref_primary_10_1111_bjd_18904 crossref_primary_10_1016_j_jaad_2020_09_050 crossref_primary_10_1111_jdv_19520 crossref_primary_10_1016_j_tranon_2021_101220 crossref_primary_10_1038_s41598_022_19135_2 crossref_primary_10_1080_14728222_2024_2375373 crossref_primary_10_3390_metabo12080688 crossref_primary_10_1016_j_xjidi_2025_100397 crossref_primary_10_1093_cei_uxae052 crossref_primary_10_3390_ijms22105182 crossref_primary_10_1016_j_eclinm_2025_103297 crossref_primary_10_1080_1744666X_2020_1719833 crossref_primary_10_1007_s15011_023_6024_0 crossref_primary_10_1111_exd_14647 crossref_primary_10_1016_j_compbiolchem_2024_108089 crossref_primary_10_1111_ijd_70053 crossref_primary_10_3390_ijms26188969 crossref_primary_10_1002_hed_26575 crossref_primary_10_1186_s13046_021_02221_0 crossref_primary_10_1136_ard_2023_224049 crossref_primary_10_3390_nano14211760 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamadermatol.2019.3056 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6084 |
| ExternalDocumentID | 31617868 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GroupedDBID | 0R~ 4.4 53G AAWTL ABJNI ACGFS ADBBV AENEX AFOSN AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BCGUY BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EMOBN EX3 NPM OB3 OBH OGROG OHH OVD PQQKQ RAJ SV3 TEORI WOW 7X8 |
| ID | FETCH-LOGICAL-a413t-dc97ed9036710b54c1c2239075b77a7a0b8b0762d407bc8c7d59c8e355204ec82 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 117 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000505184900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2168-6084 |
| IngestDate | Wed Oct 01 14:25:19 EDT 2025 Thu Jan 02 22:27:46 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a413t-dc97ed9036710b54c1c2239075b77a7a0b8b0762d407bc8c7d59c8e355204ec82 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 31617868 |
| PQID | 2306216215 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2306216215 pubmed_primary_31617868 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-01 |
| PublicationDateYYYYMMDD | 2019-12-01 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA dermatology (Chicago, Ill.) |
| PublicationTitleAlternate | JAMA Dermatol |
| PublicationYear | 2019 |
| SSID | ssj0000800431 |
| Score | 2.5978246 |
| SecondaryResourceType | review_article |
| Snippet | The risk of cancer developing in people with psoriasis has raised some concern, with little clarity regarding differentiation in risk according to psoriasis... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1390 |
| SubjectTerms | Comorbidity Humans Incidence Mortality Neoplasms - epidemiology Observational Studies as Topic Psoriasis - diagnosis Psoriasis - epidemiology Risk Assessment - statistics & numerical data Risk Factors SEER Program - statistics & numerical data Severity of Illness Index |
| Title | Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31617868 https://www.proquest.com/docview/2306216215 |
| Volume | 155 |
| WOSCitedRecordID | wos000505184900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA_qRHzx-2N-EcHXaPqRNPVFxnT44MbwA_c20iTFIrRzrYL_vZc2m74IglBKISSE3PXud3e5O4TOvJTD_vyESDBoSchoQKStjMi40B5VNFW0ThS-iwYDMRrFQ-dwK921yplMrAW1LpT1kV9YqOx78LCryRuxXaNsdNW10FhErQCgjOXqaCTmPhaLhsK6JSHMFIRTEc6ShF3hIW3FX1XYGIQXn1s4_TvSrDVOb_2_e91Aaw5r4k7DHJtoweRbaKXvounbKP9BG1ykeFjCIrLMSvycVS8YoCG-z8pXO3Q9z63CxRRff9YfKe5anple4g5-mFeExk24Actc476pJJGu7skOeurdPHZvieu_QCSotopoFUdGx6DjAIYkLFSeAjAB1jRLokhGkiYioSBMNRiFiRIq0ixWwgCC8WlolPB30VJe5GYfYW4491OthGRxyBJYRDMh_VjxIGRpGrbR6ewkx8DfNmghc1O8l-Pvs2yjvYYc40lTiGMcWONMcHHwh9mHaNXSuLmJcoRaKfzd5hgtq48qK6cnNePAezDsfwELJ8yg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+Psoriasis+With+the+Risk+of+Developing+or+Dying+of+Cancer%3A+A+Systematic+Review+and+Meta-analysis&rft.jtitle=JAMA+dermatology+%28Chicago%2C+Ill.%29&rft.au=Trafford%2C+Alex+M&rft.au=Parisi%2C+Rosa&rft.au=Kontopantelis%2C+Evangelos&rft.au=Griffiths%2C+Christopher+E+M&rft.date=2019-12-01&rft.issn=2168-6084&rft.eissn=2168-6084&rft.volume=155&rft.issue=12&rft.spage=1390&rft_id=info:doi/10.1001%2Fjamadermatol.2019.3056&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6084&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6084&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6084&client=summon |